Trial Profile

Phase 1/2 investigator sponsored expansion trial of agenT-797 in combination with standard of care agents (pembro/nivo) with or without botensilimab (a multifunctional CTLA-4) in relapsed/refractory NSCLC, testicular cancer, and in 2L gastric cancer

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 18 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AGENT-797 (Primary) ; Botensilimab (Primary) ; Nivolumab; Pembrolizumab
Indications Gastric cancer; Non-small cell lung cancer; Testicular cancer
Focus Therapeutic Use

10 Aug 2023 According to a MiNK Therapeutics media release, randomized phase 2 trial in 2L metastatic gastric cancer planned to launch at Memorial Sloan Kettering Cancer Center
11 May 2023 According to a MiNK Therapeutics media release, the company is initiating phase 1/2 expansion studies in NSCLC and gastric cancer, with majority costs planned for external, non-dilutive grant funding.
20 Apr 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com